<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02353858</url>
  </required_header>
  <id_info>
    <org_study_id>HT01</org_study_id>
    <nct_id>NCT02353858</nct_id>
  </id_info>
  <brief_title>Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer</brief_title>
  <acronym>HT01</acronym>
  <official_title>Preoperative Radiochemotherapy With Concurrent Deep Regional Hyperthermia for Locally Advanced Rectal Cancer. A Prospective Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current trial is evaluating the impact of deep regional hyperthermia on the pathological
      complete response rate in locally advanced rectal cancer in the context of preoperative 5FU
      based radiochemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate</measure>
    <time_frame>After surgical resection (4-6 weeks after last radiotherapy fraction)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Locoregional progression free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastases free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyperthermia treatments</measure>
    <time_frame>At completion of hyperthermic radiochemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic treatment related toxicity, according to CTC criteria</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post operative morbidity</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Locally Advanced Rectal Cancer</condition>
  <condition>Hyperthermia</condition>
  <condition>Hyperthermic Radiochemotherapy</condition>
  <condition>Hyperthermic Chemoradiotherapy</condition>
  <condition>Deep Regional Hyperthermia</condition>
  <arm_group>
    <arm_group_label>RtChx + Hyperthermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy: 5 x 1,8 Gy/Week, cumulative dose 50,4 Gy (ICRU) Chemotherapy: 5-fluorouracil d1-5 and d29-d33 Deep regional hyperthermia: 2x/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Deep regional hyperthermia</intervention_name>
    <description>Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42째C.</description>
    <arm_group_label>RtChx + Hyperthermia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.</description>
    <arm_group_label>RtChx + Hyperthermia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy (5-Fluorouracil)</intervention_name>
    <description>5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.</description>
    <arm_group_label>RtChx + Hyperthermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically confirmed Adenocarcinoma of the rectum (up to 10 cm from the anal
             verge)

          -  International Union Against Cancer stages II or III

          -  ECOG PS 0/2

          -  Informed consent

        Exclusion Criteria:

          -  Congestive heart failure (NYHA III/IV)

          -  History of myocardial infarction within the last 6 months.

          -  AV Block III

          -  Total hip replacement or major metal pelvic implants

          -  Cardiac pacemaker

          -  Contraindications for radiochemotherapy

          -  Contraindications for surgical tumor resection

          -  Previous pelvic radiotherapy or chemotherapy

          -  Active chronic inflammatory bowel disease

          -  Collagenosis

          -  Congenital diseases with increased radiosensitivity

          -  Pregnancy or breastfeeding

          -  Secondary malignancies other than locally controlled basalioma or in-situ carcinomas
             Infiltration of the anal canal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital T체bingen, Department of Radiation Oncology</name>
      <address>
        <city>T체bingen</city>
        <state>Baden-W체rttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Hyperthermia</keyword>
  <keyword>Radiochemotherapy</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Deep regional hyperthermia</keyword>
  <keyword>pathologic complete response</keyword>
  <keyword>Regression Grade</keyword>
  <keyword>Locally advanced rectal cancer</keyword>
  <keyword>complete response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

